Covid-19

The best way to flatten the curve for coronavirus pandemic is mass testing.
Governments prefer coronavirus specific antibody, immunochromatography testing for mass screening, whether symptoms are observed or not, to determine who can go back to normal daily life.
Test volumes are on the rise, however even in the most diligent countries % of population tested remains less than 5%.

GNZ – COVID 19 is a rapid immunochromatography test for diagnosis of two scenarios:

whether a patient is currently infected by COVID-19 can be diagnosed from the first day of infection using swap samples from throat and nose and by detecting virus specific surface proteins and antigens

whether a patient has been infected in the past by COVID-19 can be determined using a blood sample and screening his/her body’s immune response to the infection, i.e. whether COVID-19 specific IgG, IgM antibodies have been developed.

Both tests give results in less than 15 minutes and do not require a laboratory facility.

GNZ – COVID 19 is currently at beta prototype stage. As of May 2020, GNZ – Covid 19 has been awarded a grant of 563k TL from Scientific and Technological Research Council of Turkey (TUBITAK)

Our Mission on Covid-19

  • Control is only possible through mass testing
  • Testing helps us with 2 stages of controlling the pandemic, the first is diagnosis of the infected patients via virus specific molecular tests and the second is identifying recovered patients via immunochromatography (rapid test).
  • While getting ready for the post Covid-19 state we understand the importance of being technologically prepared for post corona stage and the future pandemics.  That’s why we started develop Sars-Cov-2 specific diagnostic rapid tests and virus specific anti-human antibody/antigen rapid tests and a standardized screening device.

Our solution CoV2 Biochip Device

BioChip
Higher accuracy and sensitivity microfluidic diagnostic testing chip, embedding monoclonal anti-human COVID-19 specific antigens/antibodies, fluorescence tagged.

BioChip Screening System
Quantitative fluorescence reading system with an advance image processing software to detect and count COVID-19 units in the sample.

Product

BioChip
Higher accuracy and sensitivity microfluidic diagnostic testing chip, embedding monoclonal anti-human COVID-19 specific antigens/antibodies, fluorescence tagged.

BioChip Screening System
Quantitative fluorescence reading system with an advance image processing software to detect and count COVID-19 units in the sample.

Biofluidic chips

Biofluidic Chips

Monitoring Device

Monitoring device

Monitoring Device

COVID-19 specific Antigen/antibodies

Optimization

The first biochip system system for COVID-19 rapid diagnosis. Bochips (biofluidics) are manufactured in clean room with a manufacturing band. PDMS based silicon chips 10µ – 100µ height %40 more standardized for low concentration samples. After microfluidic cassettes are manufactured their surface is activated with plasma and coated with conjugate (antigen/antibody) for detection of COVID-19 antibodies/antigens

Virus Specific Antigen

COVID-19 specific antibodies High sensitivity and specificity production time 50 days (hybridoma) Enough production for 900.000 test Antigens are produced in mammalian cells, working sensitive for diagnosis First test results = 39 / 40 Ready for 2nd trial after 5 weeks *100 clinical trial is minimum requirement for FDA Emergency Use Authorization

Biochip Screening System

One of the 3 devices in the world, for COVID-19 diagnosis (rapid tests) Automatization test reading brings standardization and quantitative results instead of ‘‘YES-NO’’ We developed prototypes with our previous experience at cell detection and countering systems.